Candel Therapeutics, Inc.

NASDAQ:CADL

Biotechnology

Healthcare
$5.32 +0.56%

+$0.05 today

Market cap
$417.33M
Beta
-0.48
P/E (TTM)
-9.2
EPS (TTM)
-$0.87
52W Low $4.35High $9.57

Volume 1.39M

Average 1.82M

CADL Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Candel Therapeutics, Inc.NASDAQ: CADL

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $9.84M rose 145.0% year over year, ahead of the +88.9% change in trailing-twelve-month research & development. Sequentially, it fell 10.8% from the prior quarter. Over 3 fiscal years it compounded at +13.6% a year.

Context

  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +145.0% holds above the trailing-twelve-month pace of +88.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.84M-10.8% QoQ
Last fiscal yearDec 2025
$30.5M+57.9% YoY
LTMMar 2026
$36.32M+88.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+145.0%——
1 year+57.9%——
3-year CAGR+13.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
30.5M USD
Year-over-year change
+57.9%
4-year CAGR
+19.1%

Research & Development vs competitors

How CADL compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +88.9% is the 2nd highest of 10, against a peer median of -0.1%.
  • Over three fiscal years its annual growth of +13.6% compares with a peer median of +5.9%.
CADL Competitors
Research & Development for CADL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$255.99M USD+3.7%+29.7%117.9%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$241.88M USD-19.7%+0.6%63.8%
MGNXMacroGenics, Inc.LTM Mar 2026$135.36M USD-19.9%-12.2%86.2%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$116.62M USD-0.1%+21.2%—
IPSCCentury Therapeutics, Inc.LTM Mar 2026$83.18M USD-24.7%-0.5%—
PBYIPuma Biotechnology, Inc.LTM Mar 2026$68M USD+23.2%+5.9%29.9%
CADLCandel Therapeutics, Inc.LTM Mar 2026$36.32M USD+88.9%+13.6%—
GNLXGenelux CorporationLTM Mar 2026$20.4M USD+3.6%+29.8%254962.5%
IMMXImmix Biopharma, Inc.LTM Mar 2026$20.26M USD+102.3%+57.1%—
NBPNovaBridge BiosciencesLTM Sep 2025CN¥13.28M CNY-94.8%-61.3%—
Peer median (excluding CADL) —-0.1%+5.9%86.2%

Competitors are the stored peer set for CADL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue125K125K000
Cost of Revenue00000
Gross Profit125K125K000
Gross Margin100.0%100.0%———
Research & Development15.18M20.79M24.51M19.31M30.5M
Selling, General & Admin10.67M14.06M13.89M14.06M17.77M
Operating Expenses24.78M34.8M38.39M33.37M48.27M
Depreciation & Amortization232K778K960K990K845K
EBITDA(24.42M)(16.31M)(34.38M)(52.1M)(35.22M)
EBITDA Margin-19534.4%-13046.4%———
Operating Income(24.65M)(34.67M)(38.39M)(33.37M)(48.27M)
Operating Margin-19720.0%-27739.2%———
Interest Income01.22M2.08M1.09M3.92M
Interest Expense53K1.71M2.6M2.09M2.12M
Other Income / Expenses(10.4M)15.93M452K(21.81M)10.08M
Income Before Tax(36.12M)(18.79M)(37.94M)(55.18M)(38.18M)
Pre-Tax Margin-28899.2%-15035.2%———
Income Tax Expense00000
Net Income(36.12M)(18.79M)(37.94M)(55.18M)(38.18M)
Net Margin-28899.2%-15035.2%———
EPS (Basic)(1.26)(0.10)(1.31)(1.74)(0.72)
EPS (Diluted)(1.26)(0.10)(1.31)(1.74)(0.72)
Weighted Avg Shares28.69M28.82M28.94M31.68M52.96M
Weighted Avg Shares (Diluted)28.69M28.82M28.94M31.68M52.96M

Candel Therapeutics, Inc.

NASDAQ:CADL

Intrinsic Alpha fair value

Locked

Current Price

$5.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.